TG103
Sources
registry, as of 2025-08-11Stale
https://clinicaltrials.gov/study/NCT05997576
A Study of TG103 Injection in Non-diabetic Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Enrollment 675. Conditions Overweight or Obesity. This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase 3 study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of TG103 injection, a GLP-1 receptor agonist, for weight management in non-diabetic patients with BM
ClinicalTrials.gov NCT05997576 protocol and results modules
registry, as of 2025-05-14Stale
https://clinicaltrials.gov/study/NCT06226090
A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Enrollment 314. Conditions Obesity; Overweight. This study is a randomized, double-blind, placebo-controlled, parallel phase 2 study to evaluate efficacy, safety, pharmacokinetic characteristics and immunogenicity of TG103 injection for weight management in non-diabetic patients with overweight in the presence of comorbidities
ClinicalTrials.gov NCT06226090 protocol and results modules
registry, as of 2021-10-01Stale
https://clinicaltrials.gov/study/NCT05063253
A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes. Overall status UNKNOWN. Phases PHASE2. Lead sponsor CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Enrollment 208. Conditions Type 2 Diabetes Mellitus. The main purpose of this study is to evaluate the efficacy, safety, PK and PD characteristics of different doses of TG103 injection in overweight/obese subjects with type 2 diabetes mellitus.
ClinicalTrials.gov NCT05063253 protocol and results modules
registry, as of 2022-05-23Stale
https://clinicaltrials.gov/study/NCT05299697
A Study of TG103 Injection in Overweight or Obesity. Overall status UNKNOWN. Phases PHASE2. Lead sponsor CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Enrollment 195. Conditions Overweight or Obesity. This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase II study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of two dose levels of TG103 injection, a GLP-1 receptor agonist, in the management of overweight or
ClinicalTrials.gov NCT05299697 protocol and results modules
registry, as of 2023-06-22Stale
https://clinicaltrials.gov/study/NCT04855292
A Study of TG103 Injection in Overweight/Obese Subjects Without Diabetes. Overall status COMPLETED. Phases PHASE1. Lead sponsor CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Enrollment 48. Conditions Diabetes. The main purpose of this study is to assess the safety and tolerability of multiple doses of TG103 injection in overweight/obese subjects without diabetes
ClinicalTrials.gov NCT04855292 protocol and results modules